Cinclus Pharma Holding AB (FRA:J8P) Total Assets: €47.50 Mil (As of Mar. 2026)


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €1.03
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Total Assets?

Cinclus Pharma Holding AB FRA:J8P +0.39% 6 Total Assets is €47.50 Mil as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Cinclus Pharma Holding AB's Total Assets for the quarter that ended in Mar. 2026 was €47.50 Mil.

During the past 12 months, Cinclus Pharma Holding AB's average Total Assets Growth Rate was 13.50% per year. During the past 3 years, the average Total Assets Growth Rate was 69.30% per year.

During the past 5 years, Cinclus Pharma Holding AB's highest 3-Year average Total Assets Growth Rate was 69.30%. The lowest was 56.30%. And the median was 62.80%.

Total Assets is connected with ROA %. Cinclus Pharma Holding AB's annualized ROA % for the quarter that ended in Mar. 2026 was -67.46%. Total Assets is also linked to Revenue through Asset Turnover. Cinclus Pharma Holding AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.02.

Cinclus Pharma Holding AB  (FRA:J8P) Total Assets Explanation

Total Assets is connected with ROA %.

Cinclus Pharma Holding AB's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-32.964/( (50.224+47.5)/ 2 )
=-32.964/48.862
=-67.46 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cinclus Pharma Holding AB's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.932/( (50.224+47.5)/ 2 )
=0.932/48.862
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cinclus Pharma Holding AB Total Assets Related Terms

Cinclus Pharma Holding AB Total Assets Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Total Assets Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
14.33 16.90 8.44 52.25 50.22

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.70 56.50 53.44 50.22 47.50
FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cinclus Pharma Holding AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=33.944+16.28
=50.22

Cinclus Pharma Holding AB's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=26.093+21.407
=47.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €47.50 Mil mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Total Assets of €47.50 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Total Assets too high?
Cinclus Pharma Holding AB's current Total Assets is €47.50 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Total Assets compare to ZTS and UTHR?
Cinclus Pharma Holding AB's Total Assets of €47.50 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Total Assets is €47.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Total Assets of €47.50 Mil. The current Total Assets is €47.50 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Total Assets is €47.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.03
Price